• Please be sure to read the rules and adhere to them. Some banned members have complained that they are not spammers. But they spammed us. Some even tried to redirect our members to other forums. Duh. Be smart. Read the rules and adhere to them and we will all get along just fine. Cheers. :beer: Link to the rules: https://www.forumsforums.com/threads/forum-rules-info.2974/

Corona Virus spreading ... US official says no need to worry

Doc said:
I have to wonder how much these companies are being paid for each vaccine? It is in their best interest to keep us having to get boosters every six months. Of course I'll be the government is paying top dollar for every vaccine. Anyone know how much has been paid out for these pokes in the arm?
Click to expand...
Just look at the 1 year or 5 year charts here: https://finance.yahoo.com/quote/MRNA?p=MRNA
 
  • Like
Reactions: Doc
Doc, I fear the government more than I do this virus.
3 of our covid residents are cleared now to go back to their rooms.
We had a trunk or treat thing last night over at the facility.
Little kiddies walking around waving at them through the windows.
They are ALL stable on the covid unit.
One lady came back from the hospital.
She was on a vent, but from what I hear, she's going to be ok.
 
We already had the first version.
Sick as hell for two weeks, coughed and had no (pardon me. spit)
Chicken soup fixed everything
 
m1west said:
if you are healthy I question the need for any of it, and I had it.
Click to expand...
I question the need for any healthy people under 50 years old to get the vaccine.

I got the vaccine because I am not healthy.

Anyone over 50, given the Delta/Indian variant's spreadability, should seriously consider vaccination. It does not appear to be statistically more lethal. It just is spreads much faster.
 
m1west said:
My cabin neighbor in his 50's got it last year, then got the shots, just got it again. I will post how it went for him in a couple weeks.
Click to expand...
The variants are changing things and making people more likely to get Covid, even those with natural and vaccine immunity. We have known that neither actually prevents reinfection but reinfection is far less likely to be severe.

Just like the seasonal flu, which is a different strain every year, is endemic it appears that Covid has become endemic too. It won't go away. And as long as we watch the risk factors and adapt we can live with this too. Statistically this is a disease that puts older people at much higher risk. Younger people are at statistically insignificant risk levels for seriously complications or death.
 
Last edited:
Notice the stats don't mention how many of these were vaccinated.
🙄
FB_IMG_1636036514944.jpg
 
Melensdad said:
The variants are changing things and making people more likely to get Covid, even those with natural and vaccine immunity. We have known that neither actually prevents reinfection but reinfection is far less likely to be severe.

Just like the seasonal flu, which is a different strain every year, is endemic it appears that Covid has become endemic too. It won't go away. And as long as we watch the risk factors and adapt we can live with this too. Statistically this is a disease that puts older people at much higher risk. Younger people are at statistically insignificant risk levels for seriously complications or death.
Click to expand...
I agree and have held that position since the beginning. Lets hope the mutations make it more mild as they go, although DELTA didn't behave that way. The focus should be on therapeutics, I would call the vaccines more of a therapeutic than a vaccine, as they don't really prevent anything. Just not enough time to see what the long term effects are, for me to get the jab, I'm going to give it some time before I make that decision.
 
Regeneron has finally released their anti-Covid cocktail. And it works.

So we have several treatments that are actually proven and which will become widely available very quickly.

Screen shot from ZERO HEDGE

Screen Shot 2021-11-08 at 6.32.40 AM.png
 
Interesting 23 minute video from Dr Campbell about Ivermectin and the new Pfizer drug (that works just like Ivermectin works). Hmmm.... maybe Ivermectin actually works?!? Oh, no you can't actually say Ivermectin works so you make a new patented drug that mirrors Ivermectin.

Spend the time it takes to watch this video.

 
m1west said:
My cabin neighbor in his 50's got it last year, then got the shots, just got it again. I will post how it went for him in a couple weeks.
Click to expand...
Cabin neighbor and wife, made it through again, the are both fully vaccinated and said that the second time with the delta variant was similar to the first time.
 
More news on viable treatments...

This from VOX https://www.vox.com/future-perfect/...t-for-covid-fluvoxamine-molnupiravir-paxlovid

For the full article see the link above but this outlines a good bit of the current and upcoming development on treatments. The article has lots of LINKS which I omitted for space considerations.

In recent months, researchers have made some advances in figuring out how to treat Covid-19 once you’ve contracted it. Of particular promise are medications available in a form that should be especially useful in the fight against the virus: pills. Pills are easy to store and ship, making them a more feasible option for worldwide distribution, and they don’t tax already overloaded hospital resources during a surge.​
​
To understand why the development of anti-Covid pills is a big deal, think about how we’ve been able to treat Covid-19 thus far. In the nearly two years since this coronavirus started spreading, we’ve learned a lot about how to care for patients who are sick enough to require hospital care. Cheap, widely available drugs such as dexamethasone have substantially reduced the hospital mortality rate for severe Covid-19.​
​
But there are fewer options for sick people who haven’t been hospitalized. The one outpatient treatment authorized for emergency use and widely available in the US is monoclonal antibodies, which work quite well but must be administered as either a single IV infusion or a series of four shots in a medical setting.​
​
Uptake of monoclonal antibodies reportedly isn’t as high as it should be, and the treatment itself, while free to US patients, is pricey, costing the US government $2,100 per dose.​
​
So as effective as monoclonal antibodies have been, there’s still a large void in our early treatment arsenal. When the virus surges in an area, hospitals get overwhelmed, meaning that people who end up needing treatment might not get it. Meanwhile, people with mild to moderate cases are told to stay home, where they have very few options.​
​
The lack of good early treatments for Covid-19 has led to high demand for drugs that have gained adherents but probably don’t help all that much, from hydroxychloroquine to metformin to ivermectin. The effort to figure out how and whether those treatments work has been marred by widespread fraud in published research investigating them.​
​
But there’s finally been some real progress on identifying Covid-19 treatments that not only are highly effective but also available for Covid-19 sufferers to take at home.​
​

Fighting Covid-19 with a pill​

One pill that’s been shown to be effective against the disease wasn’t even made to fight Covid-19.​
​
Fluvoxamine is a cheap, generic antidepressant that’s been around since the 1990s. It also appears to reduce hospitalizations and deaths by Covid-19 by up to 30 percent, according to the results of a randomized, controlled trial, the initial findings of which I reported on back in August. Results from the so-called TOGETHER study, which tested fluvoxamine and some other treatments, were recently published in The Lancet medical journal.​
​
How does fluvoxamine work in the case of Covid-19? Researchers’ best guess is that it modulates the body’s inflammatory response and reduces lung damage as the immune system fights off the coronavirus.​
​
A 30 percent reduction in hospitalizations and deaths may not strike you as particularly high, but the drug is cheap (only $4 per dose) and has a demonstrated track record of safety (it’s FDA approved), which should strengthen the case for adding it to the global arsenal in the fight against the pandemic.​
​
Despite encouraging trial results and a great safety profile, the National Institutes of Health’s treatment guidelines for fluvoxamine haven’t been updated since April, and the drug isn’t widely prescribed or recommended for Covid-19 patients. Doctors can make the call to prescribe fluvoxamine as an off-label treatment, but many might be reluctant to do so until the drug’s official guidelines incorporate evidence from large, reputable clinical studies demonstrating its efficacy. Now that the TOGETHER results have been published, though, doctors might be more willing to write those prescriptions.​
​
An even more promising pill is Merck’s molnupiravir. Unlike fluvoxamine, it’s not already FDA approved, but it’s also repurposed after a fashion: Merck began developing the antiviral as an influenza treatment. It’s taken as a batch of up to four pills, twice a day for five days.​
​
In Merck’s studies, molnupiravir reduced Covid-19 hospitalizations and deaths by about half. The UK granted the drug “conditional authorization” last week; the FDA has been reviewing the data since mid-October and will hold a hearing to discuss the data on November 30.​
​
The US government has committed to purchasing 1.7 million courses of the drug for about $700 apiece once it’s approved or authorized for emergency use. Merck has licensed the generic manufacturing of molnupiravir at a much, much cheaper price in more than 100 developing countries, and the success of that program will be key for molnupiravir to make a difference worldwide.​
​
Finally, Pfizer’s Paxlovid is a little farther away from widespread availability, but recent research suggests it might be poised to make a huge difference. Paxlovid is an antiviral developed to target Covid-19 specifically by blocking a specific enzyme the virus needs to reproduce itself.​
​
An interim analysis of an ongoing trial published by Pfizer last week noted that Paxlovid reduced the risk of hospitalization or death by 89 percent for adults at risk of severe Covid-19. That’s a huge effect size, and it’s always wise to be a little skeptical of results that good.​
​
But if the studies hold up — and there are more ongoing that could support or refute the existing data — that could effectively mean the end of the pandemic. For many people, getting sick from Covid-19 would be much less of a danger.​
​

Down the pike​

There are many other early Covid-19 treatments under development and in testing, too. For instance, researchers in the UK found that inhaled budesonide, a medication used to treat asthma, reduced recovery time, hospital admissions, and deaths in Covid-19 patients; studies are underway to confirm those results and to check how budesonide interacts with other early treatments.​
​
The antiviral remdesivir offers little benefit for Covid-19 patients and probably “makes little or no difference” in mortality, according to a systematic review of multiple studieson its effects. Gilead Sciences is developing a pill version for non-hospitalized patients in the hope that remdesivir might work better as an early treatment; some early evidence bears that out. . . .​
 
Melensdad said:
More news on viable treatments...

This from VOX https://www.vox.com/future-perfect/...t-for-covid-fluvoxamine-molnupiravir-paxlovid

For the full article see the link above but this outlines a good bit of the current and upcoming development on treatments. The article has lots of LINKS which I omitted for space considerations.

In recent months, researchers have made some advances in figuring out how to treat Covid-19 once you’ve contracted it. Of particular promise are medications available in a form that should be especially useful in the fight against the virus: pills. Pills are easy to store and ship, making them a more feasible option for worldwide distribution, and they don’t tax already overloaded hospital resources during a surge.​
​
To understand why the development of anti-Covid pills is a big deal, think about how we’ve been able to treat Covid-19 thus far. In the nearly two years since this coronavirus started spreading, we’ve learned a lot about how to care for patients who are sick enough to require hospital care. Cheap, widely available drugs such as dexamethasone have substantially reduced the hospital mortality rate for severe Covid-19.​
​
But there are fewer options for sick people who haven’t been hospitalized. The one outpatient treatment authorized for emergency use and widely available in the US is monoclonal antibodies, which work quite well but must be administered as either a single IV infusion or a series of four shots in a medical setting.​
​
Uptake of monoclonal antibodies reportedly isn’t as high as it should be, and the treatment itself, while free to US patients, is pricey, costing the US government $2,100 per dose.​
​
So as effective as monoclonal antibodies have been, there’s still a large void in our early treatment arsenal. When the virus surges in an area, hospitals get overwhelmed, meaning that people who end up needing treatment might not get it. Meanwhile, people with mild to moderate cases are told to stay home, where they have very few options.​
​
The lack of good early treatments for Covid-19 has led to high demand for drugs that have gained adherents but probably don’t help all that much, from hydroxychloroquine to metformin to ivermectin. The effort to figure out how and whether those treatments work has been marred by widespread fraud in published research investigating them.​
​
But there’s finally been some real progress on identifying Covid-19 treatments that not only are highly effective but also available for Covid-19 sufferers to take at home.​
​

Fighting Covid-19 with a pill​

One pill that’s been shown to be effective against the disease wasn’t even made to fight Covid-19.​
​
Fluvoxamine is a cheap, generic antidepressant that’s been around since the 1990s. It also appears to reduce hospitalizations and deaths by Covid-19 by up to 30 percent, according to the results of a randomized, controlled trial, the initial findings of which I reported on back in August. Results from the so-called TOGETHER study, which tested fluvoxamine and some other treatments, were recently published in The Lancet medical journal.​
​
How does fluvoxamine work in the case of Covid-19? Researchers’ best guess is that it modulates the body’s inflammatory response and reduces lung damage as the immune system fights off the coronavirus.​
​
A 30 percent reduction in hospitalizations and deaths may not strike you as particularly high, but the drug is cheap (only $4 per dose) and has a demonstrated track record of safety (it’s FDA approved), which should strengthen the case for adding it to the global arsenal in the fight against the pandemic.​
​
Despite encouraging trial results and a great safety profile, the National Institutes of Health’s treatment guidelines for fluvoxamine haven’t been updated since April, and the drug isn’t widely prescribed or recommended for Covid-19 patients. Doctors can make the call to prescribe fluvoxamine as an off-label treatment, but many might be reluctant to do so until the drug’s official guidelines incorporate evidence from large, reputable clinical studies demonstrating its efficacy. Now that the TOGETHER results have been published, though, doctors might be more willing to write those prescriptions.​
​
An even more promising pill is Merck’s molnupiravir. Unlike fluvoxamine, it’s not already FDA approved, but it’s also repurposed after a fashion: Merck began developing the antiviral as an influenza treatment. It’s taken as a batch of up to four pills, twice a day for five days.​
​
In Merck’s studies, molnupiravir reduced Covid-19 hospitalizations and deaths by about half. The UK granted the drug “conditional authorization” last week; the FDA has been reviewing the data since mid-October and will hold a hearing to discuss the data on November 30.​
​
The US government has committed to purchasing 1.7 million courses of the drug for about $700 apiece once it’s approved or authorized for emergency use. Merck has licensed the generic manufacturing of molnupiravir at a much, much cheaper price in more than 100 developing countries, and the success of that program will be key for molnupiravir to make a difference worldwide.​
​
Finally, Pfizer’s Paxlovid is a little farther away from widespread availability, but recent research suggests it might be poised to make a huge difference. Paxlovid is an antiviral developed to target Covid-19 specifically by blocking a specific enzyme the virus needs to reproduce itself.​
​
An interim analysis of an ongoing trial published by Pfizer last week noted that Paxlovid reduced the risk of hospitalization or death by 89 percent for adults at risk of severe Covid-19. That’s a huge effect size, and it’s always wise to be a little skeptical of results that good.​
​
But if the studies hold up — and there are more ongoing that could support or refute the existing data — that could effectively mean the end of the pandemic. For many people, getting sick from Covid-19 would be much less of a danger.​
​

Down the pike​

There are many other early Covid-19 treatments under development and in testing, too. For instance, researchers in the UK found that inhaled budesonide, a medication used to treat asthma, reduced recovery time, hospital admissions, and deaths in Covid-19 patients; studies are underway to confirm those results and to check how budesonide interacts with other early treatments.​
​
The antiviral remdesivir offers little benefit for Covid-19 patients and probably “makes little or no difference” in mortality, according to a systematic review of multiple studieson its effects. Gilead Sciences is developing a pill version for non-hospitalized patients in the hope that remdesivir might work better as an early treatment; some early evidence bears that out. . . .​
Click to expand...
Remdesivir saved my wife life. She only got 2 doses because her liver function deteriorated, she was in bad shape getting worse before the treatment. " little or no difference " = B.S.
 
m1west said:
Remdesivir saved my wife life. She only got 2 doses because her liver function deteriorated, she was in bad shape getting worse before the treatment. " little or no difference " = B.S.
Click to expand...
There is a lot of evidence that it has no effect on MOST people. While it is great news that it worked for your wife, she is one of the very rare people that that medication seems to help. It is generally considered, by the medical community, to be an ineffective treatment.
 
A friend of mine just got back from a trip to the uk with her parents. All double vaxed. When they got back a week ago, her mom began showing symptoms and tested positive. Then her dad became ill. He passed away 3 days ago.
 
Melensdad said:
There is a lot of evidence that it has no effect on MOST people. While it is great news that it worked for your wife, she is one of the very rare people that that medication seems to help. It is generally considered, by the medical community, to be an ineffective treatment.
Click to expand...
Like the evidence that Hydroxiechloriquin, Ivermectin and antibodies don't work?
 
NorthernRedneck said:
A friend of mine just got back from a trip to the uk with her parents. All double vaxed. When they got back a week ago, her mom began showing symptoms and tested positive. Then her dad became ill. He passed away 3 days ago.
Click to expand...
Double vaxed and still died? I thought it prevented that. Condolences to your friend for there loss.
 
Then there is Gavin Newsome, the poster boy for Vax, He got his booster then disappeared for 10 days. Word on the street is he had a bad reaction and was hospitalized. I understand the vax has worked on some folks, but for others its a condom with a hole in it.
 
m1west said:
Then there is Gavin Newsome, the poster boy for Vax, He got his booster then disappeared for 10 days. Word on the street is he had a bad reaction and was hospitalized. I understand the vax has worked on some folks, but for others its a condom with a hole in it.
Click to expand...
More than word on the street. He got both the flu and the Covid shots the same day. There are several news sources saying the was sick as a dog for 10 days.
 
m1west said:
Thats terrible, can I ask, if she was Vaccinated ?
Click to expand...
No Marty, she was not.
Last week she had called in sick.
It was all pretty quick.
We heard she had been placed on a vent because her o2 levels were dropping into the 50s. No meds or any other treatments were helping. Once I heard that I knew it wouldn't be long.
They are saying they're going to mandate the vaccine at all healthcare facilities.
While I HATE covid, at the same time I think it should be ones choice to receive it.

That said, our remaining residents on the covid unit : 3.
That's good news.
Of the dozen who were on the unit, only one suffered badly.
The others are all back in their own rooms.
 
You must log in or register to reply here.
Top